Annual Drug Patent Expiration for RINVOQ
Rinvoq is a drug marketed by Abbvie Inc and included in one NDA. It is available from a single supplier. There are seventeen patents protecting this drug.
This drug has one hundred fifty four patent family members in forty one countries.
The generic ingredient in RINVOQ is upadacitinib. One registered supplier for this compound. Additional details are available on the upadacitinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for Abbvie Inc.’s RINVOQ drug